Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, 382 481, India.
Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, 382 481, India.
Pharmacol Res. 2016 Sep;111:577-591. doi: 10.1016/j.phrs.2016.07.023. Epub 2016 Jul 25.
Triple negative breast cancer is defined as one of the utmost prevailing breast cancers worldwide, possessing an inadequate prognosis and treatment option limited to chemotherapy and radiotherapy, creating a challenge for researchers as far as developing a specific targeted therapy is concerned. The past research era has shown several promising outcomes for TNBC such as nano-formulations of the chemotherapeutic agents already used for the management of the malignant tumor. Taking a glance at paclitaxel nano formulations, it has been proven beneficial in several researches in the past decade; nevertheless its solubility is often a challenge to scientists in achieving success. We have henceforth discussed the basic heterogeneity of triple negative breast cancer along with the current management options as well as a brief outlook on pros and cons of paclitaxel, known as the most widely used chemotherapeutic agent for the treatment of the disease. We further analyzed the need of nanotechnology pertaining to the problems encountered with the current paclitaxel formulations available discussing the strategic progress in various nano-formulations till date taking into account the basic research strategies required in terms of solubility, permeability, physicochemical properties, active and passive targeting. A thorough review in recent advances in active targeting for TNBC was carried out whereby the various ligands which are at present finding its way into TNBC research such as hyaluronic acid, folic acid, transferrin, etc. were discussed. These ligands have specific receptor affinity to TNBC tumor cells hence can be beneficial for novel drug targeting approaches. Conversely, there are currently several novel strategies in the research pipeline whose targeting ligands have not yet been studied. Therefore, we reviewed upon the numerous novel receptor targets along with the respective nano-formulation aspects which have not yet been fully researched upon and could be exemplified as outstanding target strategies for TNBC which is currently an urgent requirement.
三阴性乳腺癌被定义为全球最普遍的乳腺癌之一,预后不良,治疗选择仅限于化疗和放疗,这给研究人员带来了挑战,因为他们需要开发一种特定的靶向治疗方法。过去的研究时代已经显示出几种有前途的三阴性乳腺癌治疗方法,例如已经用于恶性肿瘤治疗的化疗药物的纳米制剂。以紫杉醇纳米制剂为例,在过去十年的几项研究中已经证明了它的益处;然而,其溶解度常常是科学家们取得成功的一个挑战。因此,我们讨论了三阴性乳腺癌的基本异质性以及目前的治疗选择,并简要介绍了紫杉醇的优缺点,紫杉醇是治疗这种疾病最广泛使用的化疗药物之一。我们进一步分析了纳米技术对目前紫杉醇制剂所面临问题的需求,讨论了各种纳米制剂的战略进展,同时考虑了溶解度、渗透性、物理化学性质、主动和被动靶向所需的基本研究策略。我们对三阴性乳腺癌主动靶向的最新进展进行了全面回顾,讨论了目前正在进入三阴性乳腺癌研究的各种配体,如透明质酸、叶酸、转铁蛋白等。这些配体对三阴性乳腺癌肿瘤细胞具有特定的受体亲和力,因此可用于新型药物靶向方法。然而,目前在研究管道中还有几种新型策略,其靶向配体尚未得到研究。因此,我们回顾了许多尚未得到充分研究的新型受体靶点以及相应的纳米制剂方面,这些靶点可以作为目前迫切需要的三阴性乳腺癌的突出靶向策略。